Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

A legfontosabb adatok

Ki végzi
Sanjay Mohan
Hol
Nashville (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
1 fő vett részt
Kezdés
2023. ápr. 13.
Befejezés
2024. szept. 20.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Venetoclax
  • Decitabine
  • Cedazuridine
  • Bone Marrow Aspiration and Biopsy
  • Biospecimen Collection
A regiszteradat frissítve
2026. január 9.
Miért állt le
Study was terminated early due to lack of accrual and loss of funding.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Age >= 18 years at the time of signing the Informed Consent Form (ICF); must voluntarily sign an ICF and meet all study requirements
  • History of morphologically confirmed AML (per World Health Organization [WHO] diagnostic criteria) with evidence of disease recurrence (>= 5% blasts consistent with prior disease) that occurs after allogeneic hematopoietic cell transplantation (HCT). Patients transplanted for another indication (e.g., myelodysplastic syndrome/chronic myelomonocytic leukemia [MDS/CMML]) who relapse with AML are eligible to enroll
  • White blood cells (WBC) must be less than 25,000/ul for at least three days prior to cycle 1, day 1 (C1D1) (hydroxyurea allowed)
  • A bone marrow biopsy must be performed and tissue collected for entrance to the trial
  • Eastern Cooperative Oncology Group Performance Status of 0 - 2
  • Alanine transaminase (ALT) serum glutamic pyruvic transaminase (SGPT) and/or aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) less than or equal to 3x upper limit of normal (ULN)
  • Total bilirubin < 1.5 x ULN; Patients with Gilbert's syndrome (hereditary indirect hyperbilirubinemia) must have a total bilirubin of < 3 x ULN
  • Calculated creatinine clearance >= 30 ml/min (per the Cockroft-Gault formula)
  • Willingness to abide by all study requirements, including contraception, maintenance of a pill diary, and acceptance of recommended supportive care medications

Ki nem vehet részt

  • Prior relapse or progression while receiving venetoclax or other commercially available or investigational BCL-2 inhibitor
  • Anticancer therapy, including investigational agents =< 2 weeks or =< 5 half-lives of the drug, whichever is shorter, prior to C1D1. (Use of hydroxyurea is permitted)
  • Inadequate recovery from toxicity attributed to prior anti-cancer therapy to =< Grade 1 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version [v]5.0), excluding alopecia or fatigue
  • Radiation therapy or major surgery within 3 weeks of signing consent
  • Concurrent treatment with a non-permitted concomitant medication
  • Known chronic alcohol or drug abuse
  • Any other condition deemed by the investigator to make the patient a poor candidate for clinical trial and/or treatment with investigational agents
  • History of allogeneic HCT, or other cellular therapy product, within 3 months of signing consent
  • Clinically active acute or chronic graft versus host disease (GVHD). Patients must be off calcineurin inhibitors for at least 4 weeks to be eligible
  • Active, uncontrolled infection. Patients with infection under active treatment and controlled with antibiotics are eligible. Prophylaxis is acceptable
  • Inability to tolerate oral medication, presence of poorly controlled gastrointestinal disease, or dysfunction that could affect study drug absorption
  • Other malignancy IF currently being treated or likely to be treated in next 6 months except for basal or squamous cell carcinoma of the skin or cervical carcinoma in situ
  • Clinically significant cardiovascular disease with major event or cardiac intervention within the past 6 months (e.g. percutaneous intervention, coronary artery bypass graft, documented cardiac heart failure) as determined by the investigator
  • Active documented central nervous system leukemia
  • Pregnancy or breastfeeding females

Helyszínek itt: Egyesült Államok

  • Vanderbilt University/Ingram Cancer CenterNashville, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This phase II trial tests how well decitabine and cedazuridine (DEC-C) works in combination with venetoclax in treating acute myeloid leukemia (AML) in patients whose AML has come back after a period of improvement (relapse) after a donor stem cell transplant. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving DEC-C in combination with venetoclax may kill more cancer cells in patients with relapsed AML.

A vizsgálat csoportja

  • Treatment (Venetoclax, DEC-C)A vizsgált kezelés

    Patients receive venetoclax PO daily for 28 days in a 28-day cycle. Patients receive DEC-C PO daily on days 1-5 of a 28-day cycle. Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study.

    Kezelés: Venetoclax, Decitabine, Cedazuridine, Bone Marrow Aspiration and Biopsy és Biospecimen Collection

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Phase 2 Study of Decitabine and Cedazuridine in Combination With Venetoclax for AML Relapse After Allogeneic Hematopoietic Cell Transplantation
A regiszteradat frissítve
2026. január 9.